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OPINION 
Heavy ion carcinogenesis and human space exploration 
 
Marco Durante, and Francis A. Cucinotta 
 
Abstract:  Prior to the human exploration of Mars or long duration stays on the Earth’s 
moon, the risk of cancer and other diseases from space radiation must be accurately 
estimated and mitigated. Space radiation, comprised of energetic protons and heavy 
nuclei, has been show to produce distinct biological damage compared to radiation on 
Earth, leading to large uncertainties in the projection of cancer and other health risks, 
while obscuring evaluation of the effectiveness of possible countermeasures. Here, we 
describe how research in cancer radiobiology can support human missions to Mars and 
other planets.   
 
Introduction: 
Space radiation is comprised of high energy protons and high charge (Z) and energy (E) 
nuclei (HZE), whose ionization patterns in molecules, cells, and tissues, and the resulting 
initial biological insults are distinct from typical terrestrial radiation. The relationships 
between the early biological effects of HZE nuclei and the probability of cancer in 
humans are poorly understood1-3, and it is this missing knowledge that leads to large 
uncertainties in projecting cancer risks (Figure 1), thus representing a major barrier to 
safe space exploration. Optimizing operational parameters such as the length of space 
missions, crew selection for age and gender, or applying mitigation measures such as 
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radiation shielding or use of biological countermeasures can be used to reduce risk. 
However, these procedures are clouded by uncertainties, which limit space agencies 
ability to judge the effectiveness of operational parameters and mitigation measures. 
Thus, reducing uncertainties by improving our knowledge of cancer radiobiology is the 
most cost-effective approach for solving the problem of space radiation for the Mars 
missions and beyond.  
Space exploration is a high risk endeavour with the prospects of vehicle or life 
support system failure always a large concern4,5. Acceptable levels of risk must be put 
into perspective of the value of the mission for humanity and science, the stake-holders 
for risk acceptance, and the risk-benefit ratio6. A goal of less than a 1% mission failure 
risk is used in the design of launch, life support, and crew return systems. Radiation risks 
must be considered in addition to these other mission risks, including the differences in 
the detriment from a launch failure or a cancer morbidity and death that would be 
projected to occur several to many years after the mission. The National Aeronautics and 
Space Administration (NASA) sets risk acceptance levels at 3% risk of exposure induced 
death (REID) for radiation carcinogenesis. This level is several times higher than other 
mission design risk levels, which is appropriate because of the differences in life-loss. 
Risk levels much higher than 3% would be difficult to accept because of safety grounds 
but also because other fatal radiation risks such as heart and digestive diseases7 become 
likely at higher exposure levels, thus making the radiation risk even more problematic. 
Furthermore, overall uncertainties in space radiation cancer projections are about 5–fold 
times higher at the 95% confidence level8,9 than the median risk projection and it is not 
possible, with the current state of knowledge of cancer biology, to judge if risks are 
DRAFT Nature Cancer Reviews- Perspective 
3 
higher or lower than safety standards. These facts further support that improving the 
understanding of the biology of cancer risks from space radiation exposure is the primary 
hurdle for a Mars mission.  
Research in this field is also essential for heavy-ion cancer therapy 
(hadrontherapy), where beams of high-energy carbon ions are used to sterilize solid 
cancers 10-11. One major problem related to this treatment is the risk of secondary cancer, 
especially for  pediatric patients12, 13. Information on heavy ion cancer risk, sought by 
researchers in space radiation, is also essential to estimate the incidence of secondary 
malignancies in these patients, and therefore the two research fields share many common 
topics14. 
 
Cancer Risk Estimates From Space Radiation 
Figure 2 provides a physics primer on space radiation types and the differences in energy 
deposition in biomolecules, cells, and tissues. The differences in physical characteristics 
of celestial versus terrestrial radiation make the usage of absorbed dose to compare 
radiation types extremely limited. Nevertheless, epidemiological data, largely from the 
Atomic bomb survivors in Japan7,15 and patients exposed to therapeutic radiation which 
provides a basis for risk estimation for γ-ray or X-ray exposure, is presently scaled to 
heavy ion effects. A key  assumption in current methods to project cancer risk is that a 
radiation cancer mortality rate based on epidemiological studies of the Atomic bomb 
survivors can be scaled to other populations, dose-rates, and radiation types. Two scaling 
parameters with large uncertainties are the “radiation quality factor” Q, that estimates the 
increased effectiveness of HZE nuclei compared to γ-rays for the same dose, and the 
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dose- and dose-rate effectiveness factor (DDREF) that reduces estimates of cancer risk at 
high dose- and dose-rates when the dose- and dose-rate are low (< 0.05 Gy/hr). Risks for 
extended missions to the moon and the Mars exploration mission exceed 3% for most 
Mars mission scenarios with upper 95% confidence levels near 15% risk of death9. The 
scaling of mortality rates for space radiation risks to astronauts to the Atomic bomb 
survivors introduces many uncertainties1,2,8  into risk estimates (Figure 1), and there are 
important questions with regard to the correctness of any scaling approach because of 
qualitative differences in the biological effects of HZE ions and γ-rays. 
 
Biological Effectiveness of Energetic Heavy Ions 
Energy deposition 
The initial biophysical events induced by radiation in biomolecules, cells and tissues are 
key to understanding differences between γ-rays and the heavy ions in space.  Energy 
deposition by HZE nuclei is highly heterogeneous with a localized contribution along the 
trajectory of each particle and lateral diffusion of energetic electrons (δ-rays) many 
microns from the ions path16, 17. These particles are therefore densely ionizing, i.e. have a 
high linear energy transfer (high-LET) along the primary track, however contain a 
sparsely ionizing (low-LET) component due to the high-energy electrons ejected by ions 
as they traverse tissue. The dose deposited in a biomolecule is described by 
microdosimetry concepts such as the mean specific energy and number of events (Figure 
2). For both low- and high-LET radiation, mean specific energy of millions of Gray 
(Gy=J/kg) occur for a small DNA segment with heavy ions several times more effective 
than X-rays17,18. Differences between radiation types also occur at the level of 
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chromosomal loops or whole chromosomes leading to distinct spatial patterns of DNA 
lesions for HZE nuclei and X-rays19.  These differences between radiation types occur 
due to correlations between damages in nearby sites and the event distribution which can 
extends out many microns for energetic HZE nuclei.   
 
DNA damage 
 Biophysical models show that the energy deposition events by high-LET 
radiation produce differential DNA lesions, including complex DNA breaks, and that 
there are qualitative differences between high- and low-LET radiation both in the 
induction and repair of DNA damage 2020-23. The number of DNA single-strand breaks 
(SSB) and double-strand breaks (DSB) produced by radiation varies little with radiation 
type, but  for high-LET radiation, a higher fraction of DNA damages are complex, i.e. 
clusters containing mixtures of two or more of the various types of damages (SSB, DSB, 
etc.) within a localized region of DNA. Complex damage is uncommon for endogenous 
damage or low-LET radiation, and has been associated with the increased relative 
biological effectiveness (RBE) of densely ionizing radiation24,25.  
The repair of DSB is known to occur through the non-homologous end-joining 
(NHEJ) and homologous recombination (HR) pathways26-29. Foci experiments using 
immunohistochemistry for anti-bodies of important NHEJ and HR repair proteins have 
been performed recently with X-rays and HZE nuclei. The histone variant, H2AX, which 
is a beacon for DSBs, is phosphorylated by members of the phosphoinositide-3-kinase-
realted protein kinase (PIKK) family, which includes the catalytic sub-unit of DNA-PK, 
DNA-PKcs, ataxia-telangiectasia mutated (ATM), and the ataxia-telangiectasia and Rad3-
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related (ATR) proteins30. The activated form of H2AX, denoted γ−H2AX, covers a 2 
Mbp region around a DSB31. Key differences between X-rays and HZE nuclei are already 
apparent from these early foci events including a dynamic and larger foci size in the first 
2-hrs post-irradiation for HZE nuclei compared X-rays32 and the appearance of streaks of 
foci indicating the path of a particle track, and the slower removal and persistence of foci 
for HZE nuclei34. Other DNA repair proteins35-37 such as Artemis ATM, and NBS1 may 
play a large role in the repair of complex DSBs and are a focus of space radiation 
research. 
Live cell imaging of DNA repair proteins induced with a micro-laser is now 
widely used to study the kinetics of DNA damage responses 38-40.  Live cell imaging with 
heavy ions has shown that DNA repair proteins are recruited at sites of heavy ion hits in 
cell nuclei of fibroblast cells within seconds, and no large scale chromatin movements are 
associated to the repair activity41, yet some movement is observed in the repair protein 
foci. Image analysis for the dynamics of γ−H2AX and 53pb1 proteins in human epithelial 
cells fixed following exposure to Fe-ions suggest that DNA lesions are indeed moved to 
nuclear sub-domains for more efficient repair42.  
 
Chromosomal aberrations 
DNA DSBs misrepaired or left unrepaired eventually appear as chromosomal 
aberrations43. Heavy charged particles are very effective at producing chromosomal 
exchanges with RBE values exceeding 30 in interphase (as visualized using premature 
chromosome condensation) and 10 at the first post-irradiation mitosis for energetic heavy 
ions44. However, lower values are observed in vivo45-46.  Besides, cytogenetic studies 
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point to a much higher complexity in the chromosomal rearrangements induced by heavy 
ions compared to sparsely ionizing radiation (Figure 3) – i.e. rearrangements induced by 
heavy ions involve a higher number of chromosomes and breaks47, and include both 
intra- and inter-chromosomal exchanges48, 49. Most of these complex rearrangements, 
however ultimately lead to cell death. In fact, only a few complex exchanges are found in 
the bone marrow of mice after one week exposure to Fe-ions46, and the fraction of 
aberrant cells in the progeny of human lymphocytes exposed to heavy ions is close to the 
frequency observed in samples exposed to γ-rays50 (Figure 3, panel E).  
Interestingly, chromosomal aberrations can be measured in the astronauts’ blood 
lymphocytes and can then be used to test dose and risk estimates from current models51. 
In fact, chromosomal aberrations in the blood lymphocytes are considered a validated 
biomarker of cancer risk51-53, and can be used as biodosimeters to estimate equivalent 
dose in exposed individuals54. Biodosimetry studies performed by NASA55-56 and in 
Russian cosmonauts57 show that the measured chromosomal rearrangements in 
crewmembers returning from space flight are consistent with current models, although 
the biological results are also affected by a large experimental uncertainty at low doses.  
However, yields of translocations and dicentrics decrease as a function of the time after 
exposure during the space mission, and it is unclear what the influence of the time since 
test should be on risk estimates56. Besides, for cosmonauts involved in multiple 
spaceflights, the total yield of aberrations do not seem to be additive51, and in 
experienced cosmonauts with a total of about 2 years in the final yield of the aberrations 
is close to the measured background before the first flight57. The significance of these 
findings remains to be elucidated. 
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Insights into the Molecular Mechanisms of Radiation-Induced Cancer 
The fundamental problem of space radiation risk assessment is the absence of sufficient 
proof that models of cancer risk sufficiently describe the biology of tumor formation from 
HZE nuclei, including the overarching problem of extrapolating experimental results to 
human populations or individuals. There are gaps in knowledge related to space radiation  
and carcinogenic processes that must be addressed to validate cancer projection models58 
(Figure 4). Animal studies generally demonstrate that HZE nuclei have a higher 
carcinogenic effectiveness than low-LET radiation59-62, but RBE values are difficult to 
quantify because of statistical uncertainties, which in many experiments prevents a 
conclusion on response at low dose and dose-rates. The large number of radiation types 
and energies in space precludes an extensive study of tumor types in different strains of 
mice with different ion/dose regimes. In adults the major cancers in exposed cohorts are 
lung, leukemia, breast, colorectal, and stomach7,15, however there are a large number of 
other cancers and tissues that contribute to the overall risk. There are also differences in 
background cancers in different countries and ethnic populations making the 
extrapolation of data from the Japanese A-bomb survivors to a future population of 
astronauts problematic.  Identifying the cell of origin for specific tumor types, and 
looking for similarities in the mechanisms of tumor initiation, progression and promotion 
in the mouse or in 3-dimensional human cell culture models of epithelial interacting with 
stroma cells, may serve as the best model to study differences in radiation qualities and to 
improve confidence in the model to astronaut risk extrapolation. Humanized mice offer a 
novel approach to this problem63.  
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Cat and Mouse Game, or Little Green Men?  
 Research on carcinogenesis continues to debate a fundamental question on what 
is cause or effect:  DNA damage and mutation leading to genomic instability, or 
extracellular matrix remodeling and other non-targeted effects?  For HZE nuclei such a 
fundamental question is complicated by what are the consequences of the early events 
that are already known to be different from X-rays (see Figure 3) and do they lead to an 
alien architecture on the voyage to malignancy? Tissue effects independent of DNA 
damage that have been associated with cancer initiation or progression include genomic 
instabilityP64-68P, extracellular matrix remodeling69-70, persistent inflammation71-72, and 
oxidative damage73-74. HZE nuclei will likely modify these responses, along with DNA 
changes, in ways distinct from other radiation types or carcinogens complicating our 
ability to estimate and mitigate risks. 
 
New Approaches to Cancer Risk Estimates 
Lung cancer makes-up about one-third of the cancers attributable to radiation observed in 
the Atomic-bomb survivors75 and nuclear reactor workers76. However, risk estimates are 
confounded by the use of tobacco by a large fraction of the exposed. Radiation and 
tobacco are believe to act additively, but the large tobacco risk often precludes 
identification of the radiation effect with high accuracy75,15. A very small number of 
astronauts have smoked in the past and virtually none at this time.  A new experimental 
model that allows for a novel approach to study individual or combinations of mutations 
in lung cancer progression has been recently developed77: a 3-dimensional co-culture of 
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hTERT-immortalized with cdk4 bypass of p16, bronchial epithelial cells interacting with 
a stroma layer. Over 30 primary lines have been immortalized to study how specific 
genetic components influence radiation induced transformation. The results show the 
extreme inefficiency with which X-rays transform primary cell lines. A recent report of 
the genetic makeup of lung cancers78 in a large collection of tumors shows the 
complexity of the genetic alterations involved: indeed, many of the genes involved in 
adenocarcinomas are still unknown. Studies using the 3-D co-culture models with iron 
nuclei are being carried out as well and will be especially important due to the limitations 
in animal models of human lung carcinogenesis79.  
 Research on the mechanisms of radiation-induced mammary carcinogenesis have 
highlighted the importance modifications of tissue regulation in the development of 
cancer.  Transforming growth factor β1 (TGFβ) is a tumor suppressor during cancer 
initiations and a promoter during progression80. Recent studies of TGFβ’s role in 
tumorigenesis highlight how tissues can control a broad range of cellular responses 
including how knockout of TGFβ lead to the down-regulation of the DNA damage 
responses as evidence by almost complete shut-down of γ-H2AX foci81, and induction of 
an epithelial to mesenchymal transition82 after ionizing radiation exposure in a primary 
human cell culture model.   
 
Countermeasures for Exploration of Mars and beyond 
 Even if risk projections and their uncertainties are reduced in the next few years, 
effective countermeasures to reduce the biological damage produced by radiation remains 
a long-term goal of space research. Such countermeasures may not be needed for a lunar 
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base, but probably for the Mars mission, and definitely for exploring Jupiter or Saturn’s 
moon Titan or the nearby satellites2. In all basic radioprotection textbooks, it is stated that 
there are three means to reduce exposure to ionizing radiation: increasing the distance 
from the radiation source, reducing the exposure time, and by shielding. Distance plays 
no role in space, being space radiation is omni-directional. Time in space should be 
increased rather than decreased according to the plans of exploration and colonization. 
Shielding remains as a plausible countermeasure, but a prohibitively costly in light of 
current launch mass capabilities. Furthermore, the present uncertainties in risk projection 
prevent us from determining the true benefit of shielding. Other strategies can be 
effective in reducing exposure, or the effects of the irradiation, in space. These strategies 
include the choice of an appropriate time of flight, administration of drugs or dietary 
supplements to reduce the radiation effects, and crew selection.  
 
Radioprotective agents 
The search for efficient radioprotectors is a major goal of research in radiation protection 
and therapy. Both radiation injury and oxygen poisoning occur through the formation of 
reactive oxygen species, and therefore antioxidants can be efficiently used to prevent the 
damage83. 
 Phosphorothioates and other aminothiols, which are usually administered shortly 
before irradiation, are so effective in tissue protection against ionizing radiation that one 
specific compound (Ethyol, also known as amifostine or WR-2721) is approved in many 
countries for clinical use during chemotherapy and radiotherapy cancer treatments84. 
Unfortunately, amifostine (WR-2721) and other thiols have significant side effects, 
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including nausea, vomiting, vasodilatation, and hypotension85. Therefore, it is not 
possible to use these compounds in space flights for protection against chronic exposure 
to cosmic radiation.  Natural occurring antioxidants are less effective than 
phosphorothioate agents in protection against high-dose acute radiation burden. However, 
nutritional antioxidants have a low toxicity, can be used for prolonged time, and they 
seem to play a key role in the prevention of cancer86-87. A diet rich in fruit and vegetables 
significantly reduced the risk of cancer in the A-bomb survivor cohort 88. Retinoids and 
vitamins (A, C, and E) are probably the most well-known and studied natural 
radioprotectors, but hormones (e.g. melatonin), gluthatione, superoxide dismutase, 
phytochemicals from plant extracts (including green tea and cruciferous vegetables), and 
metals (especially selenium, zinc, and copper salts) are also under study as dietary 
supplements for individuals overexposed to radiation89, including astronauts. In addition, 
there is evidence of a reduced antioxidant capacity during spaceflight, as shown by 
reduced superoxide dismutase (SOD) and total antioxidant activity in some astronauts 
returning from missions on the International Space Station90. 
Understanding the effectiveness of antioxidants in space is complicated by the 
presence of HZE particles. In principle, antioxidants should provide reduced or no 
protection against the initial damage from densely ionizing radiation, because the direct 
effect is more important than free radical-mediated indirect radiation damage at high-
LET. However, there is an expectation that some benefits should occur for persistent 
oxidative damage related to inflammation and immune responses69. Some recent 
experiments suggest at least for acute high dose irradiation that an efficient 
radioprotection by dietary supplements can be achieved even in case of exposure to high-
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LET radiation. Ascorbate reduces the frequency of mutations in human-hamster hybrid 
cells exposed to high-LET C-ions91. Vitamin A strongly reduces the induction of fibroma 
in rats exposed to swift Fe-ions 92. Dietary supplementation with Bowan-Birk protease 
inhibitors93,  L-selenomethionine or a combination of selected antioxidant agents94 could 
partially or completely prevent the decrease in the total antioxidant status in the plasma of 
mice exposed to proton or HZE particle radiation, and neoplastic transformation of 
human thyroid cells in vitro. There is evidence that dietary antioxidants (especially 
strawberries) can protect the central nervous system from the deleterious effects of high 
doses of HZE particles 95.  However, because the mechanisms of biological effects are 
different for low dose-rate compared to acute irradiation, new studies for protracted 
exposures will be needed to understand the potential benefits of biological 
countermeasures. 
Even if antioxidants can act as radioprotectors, this does not necessarily translate 
in an advantage for the cancer risk. If antioxidants protect cells by rescuing them from 
apoptosis, then this may allow the survival of damaged cells, which eventually can 
initiate tumor progression. Concern on this possibility is sustained by a recent meta-study 
of the effects antioxidant supplements in the diet of normal subjects96.   The authors did 
not find statistically significant evidence that antioxidant supplements have beneficial 
effects on mortality. On the contrary, they concluded that  β-carotene, vitamin A, and 
vitamin E seem to increase the risk of death.  Concerns not only include rescuing cells 
that still sustain DNA mutations, but also the altered methylation patterns that can result 
in genomic instability97. An approach to target damaged cells for apoptosis may be 
advantageous for chronic exposures to galactic cosmic radiation (GCR). Radioprotectors 
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tested for acute exposures at high doses should be used with care – rescuing cells may 
make the problem worst in the long term. 
 
Individual susceptibility 
Studying the mechanisms of genetic sensitivity provides important insights into the 
understanding of radiation risks to astronauts. Studies of historical data sets such as the 
atomic-bomb survivors comes with the caveat that sub-sets of the exposed cohorts could 
have a higher radiation risks and therefore skew the assessments of an average responder 
in the population upward. Mechanistic studies of DNA repair genes such as ATM, NBS1, 
and Artemis, and of signal transduction proteins such as TGF-β, EGFR, and p53  and 
their impacts on radiation sensitivity improve our understanding of space radiation 
effects.  
Therapeutic misadventures involving ataxia-telangiectasia (AT) patients have 
dramatically demonstrated the importance of genetic susceptibility to radiation damage in 
cancer treatment. ATM homozygotes only represent a small fraction of the radiosensitive 
patients, although they appear to be the most sensitive. ATM heterozygotes, who are also 
cancer-prone, are suspected to represent a large fraction of the extreme radiosensitive 
patients98. It has been shown that cells heterozygous for ATM mutations are slightly more 
sensitive to radiation-induced neoplastic transformation than the wild-type99. An 
increased sensitivity of ATM heterozygotes has been also proved in vivo, measuring the 
induction of cataracts in ATM homozygotes, heterozygotes, and wild-type mice exposed 
to 0.5-4 Gy X-rays100. Besides ATM, the issue is whether low penetrance genes can 
determine sensitivity to radiation-induce cancer. A recent study on subjects exposed to 
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high radiation doses to treat ringworm of the scalp (tinea capitis) in Israel revealed a 
strong familiar risk of radiation-induced meningioma101, suggesting that radiation 
carcinogenesis might be an issue for a genetically predisposed subgroup of the general 
population, rather than a random event102.   
It is not known if individuals displaying hypersensitivity to ionizing radiation will 
be hypersensitive to the same level to HZE nuclei as low LET irradiation, or if findings at 
high dose and dose-rates will hold at low dose-rate and doses. Mice heterozygous for the 
ATM gene are more sensitive to cataractogenesis than wild-types not only after exposure 
to X-rays, but also after localized irradiation with high-energy Fe-ions103. However these 
and other studies show that high LET irradiation has a reduced dependence on genetic 
background compared to low LET irradiation. 
 A predictive assay able to identify radiation hypersensitive or cancer-prone 
subjects could be useful in crew selection for long-term space flights. However, this assay 
is neither scientifically achievable or within society norms in most countries at the 
present time. Ultimately, for a high risk and high cost endeavor such as a mission to 
Mars, screening astronauts with increased resistance to space radiation may be sought in 
order to reduce the costs of the missions.  
 
Shielding 
For terrestrial radiation workers, additional protection against radiation exposure is 
usually provided through increased shielding. Unfortunately, shielding in space is 
problematic, especially when GCR is considered. High-energy radiation is very 
penetrating: a thin or moderate shielding is generally efficient in reducing the equivalent 
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dose, but as the thickness increases, shield effectiveness drops (see cancer risk estimates 
as a function of shielding thickness in Figure 2). This is the result of the production of a 
large number of secondary particles, including neutrons, caused by nuclear interactions of 
the GCR with the shield. These particles have generally lower energy, but can have 
higher quality factors than incident cosmic primary particle. 
 Contrary to the shielding of photons on Earth, where heavy elements such as lead 
are preferred, in space shielding effectiveness per unit mass is  the highest for hydrogen, 
and decreases by increasing the target atomic number AT. In fact, computer models (such 
as the HZETRN used by NASA or Geant4 used by ESA), accelerator and flight 
measurements, clearly show that light, highly hydrogenated materials provide the best 
protection against space radiation104-108. Liquid hydrogen should display the maximum 
performance as shield material. Hydrogen is not a practical shield material, being a low 
temperature liquid. So far, it appears that polyethylene (CH2) can be a good compromise 
(Figure 2), and in fact it has been installed in the sleeping quarters of the International 
Space Station to reduce the dose to the astronauts. Unfortunately, most of the biologically 
dangerous secondary radiation is produced in tissue by very high energy GCR nuclei 
even behind hydrogen shielding. With the current technology, active (magnetic) shielding 
is not yet feasible109-110, and passive (bulk) shields are able to reduce the exposure, but 
probably not to solve the problem105. 
   
Summary 
Space radiation,  isolation (psychosocial problems), and  microgravity-induced 
physiological changes represent the main health problems for the exploration of the Solar 
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system. However, cancer risk caused by exposure to space radiation is now generally 
considered the main hindrance to interplanetary travel, for the following reasons:  large 
uncertainties are associated with the projected cancer risk estimates;  no simple and 
effective countermeasures are available, and the large uncertainties prevent determining 
the effectiveness of countermeasures. Research is currently focusing on biological effects 
of  heavy ions, where the highest uncertainty is concentrated, using cellular, tissue, or 
animal models exposed at large nuclear accelerators. Ground-based experimentation is in 
fact the key to solve the problem of space radiation, because flight experiments are 
difficult, expensive, poorly reproducible, the dose rate is too low to get useful data in 
reasonable time, and experiments in the past have yielded no major findings111-112. The 
NASA-funded Space Radiation Health Program113 is built upon the capabilities the 
NASA Space Radiation Laboratory (NSRL) at the Brookhaven National Laboratory 
(Upton, NY, USA), and has produced experimental data in the past few years of great 
relevance for reducing uncertainty on risk assessment. The European Space Agency 
(ESA) has also recently initiated a ground-based radiobiology program114, which will be 
based at the high-energy synchrotron of the Gesellschaft für Schwerionenforschung (GSI) 
in Darmstadt (Germany) to foster European research in the field. Translation from basic 
research to cancer risk assessment is not straightforward, but for the moon base activities 
cancer risk does not appear to be a showstopper, whereas the uncertainty is still too high 
for a go/no-go decision on the mission to Mars. Radiation is certainly a major problem 
for space exploration, but it can be understood and solved. A fruitful NASA-ESA  
collaboration in accelerator-based research should be fostered in the future years, in order 
DRAFT Nature Cancer Reviews- Perspective 
18 
to reach a consensus on radiation cancer risk for a Mars mission within the next 10 years 
or so, and eventually to intensity the research on countermeasures, if urgently needed. 
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Figure 1. Uncertainties in Projecting Space Radiation Cancer Risks. 
 
Ionizing radiation is a well known carcinogen on Earth. The risks of cancer for X-rays 
and gamma-rays have been established at doses above 100 mSv, albeit there are large 
uncertainties and ongoing scientific debate about cancer risk at lower doses and at low 
dose-rates (<50 mSv/h). The major uncertainties in risk prediction are: 
• Radiation quality effects on biological damage  related to the qualitative 
and quantitative differences between space radiation compared to x-
rays  
• Dependence of risk on dose-rates in space related to the biology of 
DNA repair, cell regulation, and tissue or organism responses 
• Predicting solar particle events (SPE) including temporal, energy 
spectra, and size predictions 
• Extrapolation from experimental data to humans 
• Individual radiation-sensitivity factors including genetic, epigenetic, 
dietary or “healthy worker” effects 
The minor uncertainties in risk prediction are: 
• Data on galactic cosmic radiation (GCR) environments 
• Physics of shielding assessments related to transmission properties of 
radiation through materials and tissue 
• Microgravity effects on biological responses to radiation 
• Errors in human data  (statistical, dosimetry or recording inaccuracies) 
 
Panel A presents estimates of uncertainties for some of these factors. 
Predicting risks to individuals is difficult as there are very few quantitative measures of 
individual sensitivity. Only a select few individuals enjoy space travel and projecting 
risks for individuals rather than populations will be of utmost importance for space 
missions to Mars. The extrapolation from experimental models to humans is perhaps the 
greatest challenge to cancer risk assessments. The uncertainties are larger for astronauts 
in space compared to typical exposures on Earth as illustrated in Panel B, which shows 
the current estimates of cancer risks and 95% confidence bands for adults of age 40-yr, 
the typical age of astronauts on space missions for several terresterial exposures and 
missions on the International Space Station, a lunar colony, and the projections for a Mars 
mission. 
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Figure 2.  Space radiation physics and shielding. 
Astronauts are exposed to protons and high energy and charge (HZE) ions along with 
secondary radiation including neutrons and recoil nuclei, produced by nuclear reactions 
in spacecraft or tissue. The elemental charge of the galactic cosmic radiation (GCR) 
extends from hydrogen to uranium, however nuclei above iron (Z=26) are very infrequent 
(panel A). The energy spectrum of the GCR peaks at about 85% of the speed or light or 1 
GeV/nucleon in energy units, and consequently these particles are so penetrating that 
shielding can only partially reduce the doses absorbed by the crew.  The number of nuclei 
per unit area is denoted the fluence, F. The large ionization power of HZE ions with Z>2 
makes them the major contributor to the risk, in spite of their lower fluence than protons. 
The quantity dose (D) represents the amount of energy deposited per unit mass of 
material (unit is gray: 1 Gy= 1 J/kg) and is calculated from the fluence by multiplying it 
by the linear energy transfer (LET), L such that D = F x L.  Because the types of radiation 
in space are very diverse in how they deposit energy, this quantity is a poor descriptor of 
biological effects. To estimate biological effects it is necessary to scale radiation dose by 
a quality factor Q(LET), which varies from 1 at low LET to 30 at high LET and then 
declines at very high values because of what is called over-kill or wasted energy. The 
quantity H = D x Q is called dose equivalent and is measured in sievert (Sv). Panel A 
shows the contribution in fluence, dose, and dose equivalent of different elements in the 
GCR. In panel B we show what the energy deposition looks like in reality, a stochastic 
pattern of ionization and excitation points in biomolecules. The LET results from 
averaging this pattern over macroscopic distances. The panel C shows how the cancer 
risk for a mission to Mars varies for increasing amounts of shielding materials after 
considering the tissue shielding of the human body. Black and red lines represent water 
and aluminium shield, respectively. Lower curves are median estimates, and upper curves 
provide the upper 95% confidence limits. This calculation shows that even very heavy 
shields will not be able to reduce the risk of a large factor. 
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Figure 3. Chromosomal aberrations induced by heavy ions. 
Examples of complex-type aberrations induced by energetic Fe-ions in human peripheral 
blood lymphocytes. Complex rearrangements involve a minimum of 2 chromosomes and 
3 breakpoints. A, polycentric chromosomes visualized by mFISH: from left to right, a 
quadricentric involving both chromosomes 1, chromosome 9 and chromosome 6; a 
dicentric of chromosome 1 and 9, with an insertion of chromosome 3; a tricentric 
involving both chromosomes 6 and chromosome 1.   B, a complex rearrangement in 
chromosome 5 visualized by mBAND (courtesy of M. Horstmann). One normal 
chromosome 5 is visible on the bottom, while the other is broken in 3 pieces. Breakpoints 
can be mapped on chromosome 5 using mBAND. C, multi-aberrant karyotype, including 
inter-intrachanges in the progeny of lymphocytes exposed to Fe-ions visualized by arm-
specific mFISH (courtesy of D. Pignalosa). Arm-specific mFISH shows that complex-
rearrangements can involve both inter- and intra-chromosomal exchanges. D, fraction of 
complex-type exchanges in lymphocytes following exposure to γ-rays or Fe-ions. 
Aberrations were measured by mFISH in prematurely condensed chromosomes, and 
clearly Fe-ions induce a high fraction of complex-type rearrangements. However, many 
of these rearrangements are lethal: in fact, the RBE for the induction of aberrant cells 
(panel E) decreases from interphase (prematurely condensed chromosomes) to first 
mitosis, and to later cell-cycles (progeny of irradiated cells). This shows that many of the 
chromosomal rearrangements induced by heavy ions are not transmitted to the progeny of 
surviving cells, albeit a higher fraction of complex rearrangements is still observed in the 
survivors. 
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Figure 4. Changes en-route to malignancy for space radiation and the hallmarks of 
cancer. Terrestrial forms of ionizing radiation such as X-rays or gamma-rays induce a 
large variety of changes to DNA, biomolecules, and the microenvironment of tissues. 
Researchers have shown that HZE nuclei in space produced both qualitative and 
quantitative differences in biophysical damage compared to X-rays or gamma-rays. In 
order to accurately predict cancer risks and design countermeasure for astronaut’s, 
researchers are addressing gaps in knowledge related to how initial and developing 
biological changes as they relate to the hallmarks of cancer, differ between acute 
exposures to X-rays or gamma rays where human epidemiology data exists, to those 
produced by low doses of protons and HZE nuclei. If qualitative differences occur the 
present approach to risk estimation will have to be abandoned, while if only quantitative 
differences occur current models can be fine-tuned and uncertainties reduced through 
improved knowledge and data in experimental models of cancer risk, and confidence in 
countermeasure effectiveness will be heightened. 
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